Lilly announces a $6 billion plant in Huntsville, Alabama

Eli Lilly said on December 9, 2025 that it will invest more than $6 billion in a new active pharmaceutical ingredient (API) plant in Huntsville, Alabama, that will make small molecule synthetic and peptide medicines — including orforglipron, the company's first oral, small molecule GLP-1 receptor agonist ^[3][6]. Construction is expected to start in 2026 and finish in 2032 ^[3].

The site is the third of four new U.S. plants Lilly has said it would announce, and the company's ninth U.S. manufacturing site announced since 2020 ^[3][6]. Lilly says the project will create 450 permanent jobs — engineers, scientists, operations staff and lab technicians — plus about 3,000 construction jobs, for a combined 3,450 ^[3][6]. Another U.S. location will be announced "in the coming weeks," according to Lilly ^[6].

The campus will sit on a 260-acre site at the northeast corner of Interstate 565 and Greenbrier Parkway, in the Huntsville-Limestone County area, and was chosen from more than 300 applications, partly because it is near the HudsonAlpha Institute for Biotechnology ^[1][2][3]. Lilly plans to use machine learning, AI, digitally integrated monitoring and advanced data analytics across the site ^[3].

State and local officials described the deal in superlatives, though the exact framing differs slightly by source. Governor Kay Ivey called it "the largest initial investment in our state's history" ^[3], while the City of Huntsville described it as "the largest industrial private investment ever made in the State of Alabama" ^[2]. Huntsville says the announcement brings Lilly's total U.S. capital expansion commitments to more than $50 billion since 2020 ^[2]. CNBC reported that Lilly announced in February it would spend at least $27 billion on four new domestic plants, on top of $23 billion in prior investments since 2020 ^[4].

The GLP-1 angle

The reason this matters beyond Alabama is orforglipron. Lilly said it expects to submit the drug to global regulators for obesity by the end of 2025 ^[3][6]. CNBC reported that in November the pill won a national priority review voucher from the FDA, which could shorten the agency's assessment to potentially a few months ^[4].

Huntsville is not the only planned source of orforglipron. Lilly has also announced a $6.5 billion orforglipron site in Texas, a $1.2 billion expansion of an existing Puerto Rico facility, and a $3 billion orforglipron plant in the Netherlands, plus a $1 billion expansion in Limerick, Ireland ^[5][6]. A separate $5 billion Virginia site is for bioconjugates and monoclonal antibodies ^[5].

Competition is also part of the backdrop. Novo Nordisk has been awaiting an FDA decision on its oral version of Wegovy (semaglutide), expected in the fourth quarter of 2025 ^[5]. GlobalData has forecast that orforglipron could reach $13 billion in annual sales by 2031 and estimates a 2026 launch ^[5].

Why it matters for patients

The practical takeaway is about timing. Nothing about this plant changes supply, pricing or availability in 2026. The Huntsville facility is not expected to be complete until 2032 ^[3], so any orforglipron supply at launch would come from Lilly's other sites, such as Texas, Puerto Rico and the Netherlands ^[5][6].

What the announcement does signal is that Lilly is building capacity on the assumption that demand for an oral GLP-1 will be large and durable. Both Lilly and Novo Nordisk ran into shortages of their weekly injections when U.S. demand surged, though those issues have since eased ^[4]. Lilly's CEO David Ricks framed the Alabama investment as "onshoring of active pharmaceutical ingredient (API) production, strengthening supply chain resilience and reliable access to medicines for patients in the U.S." ^[3].

There is also a policy backdrop. Drugmakers have been expanding U.S. production amid the Trump administration's threats of tariffs on imported pharmaceuticals, including a claimed 100% tariff on branded drugs unless companies are breaking ground on U.S. plants; those tariffs have not been implemented, and concerns eased after recent drug pricing deals that exempt some companies ^[4][5].

What happens next

• End of 2025: Lilly expects to have submitted orforglipron to global regulators for obesity ^[3].
• "Coming weeks": Lilly says it will name a fourth new U.S. site ^[6].
• 2026: Construction begins in Huntsville ^[3].
• 2032: Site completion expected ^[3].

Whether orforglipron is approved, and on what timeline and label, is not yet known from these sources.